Invion Limited
IVX
Rank in Stocks
#31915
Invion Limited, an Australian clinical-stage life sciences enterprise, is... Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Share Price
$0.02266382
Last synced: 2026-11-11
Market Cap
$2.25M
Change (1 day)
-11.51%
Change (1 year)
-54.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Invion Limited (IVX)
Category
Healthcare
Operating Margin for Invion Limited (IVX)
Operating Margin as of November 2026 TTM: -1,472.22%
According to Invion Limited's latest financial reports, its current operating margin (TTM) is -1,472.22%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Invion Limited from 2006 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,472.22% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -153.68% | 282.67% |
| 2023 | -40.16% | -43.05% |
| 2022 | -70.52% | 4.51% |
| 2021 | -67.48% | 128.59% |
| 2020 | -29.52% | -54.48% |
| 2019 | -64.85% | -50.19% |
| 2018 | -130.20% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2016 | -4,456.92% | -44.32% |
| 2015 | -8,004.76% | 100.39% |
| 2014 | -3,994.55% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.69% | -100.01% |
DE
|
|
| 19.68% | -100.01% |
DE
|
|
| 13.26% | -100.01% |
JP
|
|
| 17.08% | -100.01% |
CH
|
|
| 10.53% | -100.01% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Invion Limited's operating margin
What is Invion Limited's operating margin?
Invion Limited's operating margin is -1,472.22%, as of Nov 2026.
What was Invion Limited's operating margin in 2025?
In 2025, Invion Limited's operating margin was 0.00%, compared with -153.68% in 2024.
How has Invion Limited's operating margin changed since 2020?
From 2020 to 2025, Invion Limited's operating margin was highest in 2025 (0.00%) and lowest in 2024 (-153.68%).
How does Invion Limited's operating margin compare with similar companies?
Invion Limited's operating margin (-1,472.22%) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with 19.69%.